DOI QR코드

DOI QR Code

Molecular Therapy as a Future Strategy in Endometrial Cancer

  • Thanapprapasr, Duangmani (Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University) ;
  • Thanapprapasr, Kamolrat (National Metal and Materials Technology Center (MTEC), National Science and Technology Development Agency (NSTDA))
  • Published : 2013.06.30

Abstract

Of all gynecologic cancers, endometrial cancer is the most common cancer in the US and Europe. In addition, it is presently the second most common gynecologic cancer in the world. As a result of increasing menopausal, obese and tamoxifen use women, the incidence of the cancer seems to be on the increase. Surgery is the major treatment, whereas postoperative radiation therapy in high-intermediate risk patients many prevent locoregional recurrence. Adjuvant chemotherapy can improve progression free survival in advanced or recurrent cancers. Molecular targeted therapies are now a focus of attention including anti-vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR) inhibitor and tyrosine kinase inhibitor (TKI). They may provide useful future strategies for control of endometrial malignancies in developing countries and across the world.

Keywords

Endometrial cancer;molecular therapy;VEGF;mTOR;TKI

References

  1. American cancer society (2012). Cancer Facts&Figures. Atlanta: American cancer society; 2012.
  2. Aghajanian C, Sill MW, Darcy KM, et al (2011). Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study. J Clin Oncol, 29, 2259-65. https://doi.org/10.1200/JCO.2010.32.6397
  3. Bergman L, Beelen ML, Gallee MP, et al (2000). Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet, 356, 881-7. https://doi.org/10.1016/S0140-6736(00)02677-5
  4. Bokhman JV (1983). Two pathogenetic types of endometrial carcinoma. Gynecol Oncol, 15, 10-7. https://doi.org/10.1016/0090-8258(83)90111-7
  5. Bottsford-Miller JN, Sanguino AM, Thanapprapasr D, et al (2011). Enhancing anti-angiogenic therapy by blocking focal adhesion kinase. Gynecol Oncol, 2011, 432.
  6. Coleman RL, Duska LR, Ramirez PT, et al (2011). Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol, 12, 1109-17. https://doi.org/10.1016/S1470-2045(11)70244-3
  7. Creutzberg, CL, van Putten WL, Koper PC, et al (2000). Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet, 355, 1404-11. https://doi.org/10.1016/S0140-6736(00)02139-5
  8. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  9. Fleming GF, Sill MW, Darcy KM, et al (2010). Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 116, 15-20. https://doi.org/10.1016/j.ygyno.2009.09.025
  10. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6. https://doi.org/10.1056/NEJM197111182852108
  11. Folkman J (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst, 82, 4-6. https://doi.org/10.1093/jnci/82.1.4
  12. Folkman J, Merler E, Abernathy C, et al (1971). Isolation of a tumor factor responsible for angiogenesis. J Exp Med, 133, 275-88. https://doi.org/10.1084/jem.133.2.275
  13. Grushko TA, Filiaci VL, Mundt AJ, et al (2008). An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 108, 3-9. https://doi.org/10.1016/j.ygyno.2007.09.007
  14. Howlader et al., 2012, Krapcho M, Neyman N, et al (2012). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012.
  15. Johnson N, Bryant A, Miles T, et al (2011). Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev, 10, 3175.
  16. Keys HM, Roberts JA, Brunetto VL, et al (2004). A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol, 92, 744-51. https://doi.org/10.1016/j.ygyno.2003.11.048
  17. Korets SB, Czok S, Blank SV, et al (2011). Targeting the mTOR/4E-BP pathway in endometrial cancer. Clin Cancer Res, 17, 7518-28. https://doi.org/10.1158/1078-0432.CCR-11-1664
  18. Li T, Yang Y, Li X, et al (2012). EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells. Mol Cell Biochem, 361, 19-29. https://doi.org/10.1007/s11010-011-1082-0
  19. Nimeiri HS, AM Oza, Morgan RJ, et al (2010). A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol, 117, 37-40. https://doi.org/10.1016/j.ygyno.2010.01.013
  20. Oza AM, Eisenhauer EA, Elit L, et al (2008). Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol, 26, 4319-25. https://doi.org/10.1200/JCO.2007.15.8808
  21. Oza AM, Elit L, Tsao MS, et al (2011). Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol, 29, 3278-85. https://doi.org/10.1200/JCO.2010.34.1578
  22. Parkin DM, Bray F, Ferlay J, et al (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94, 153-6. https://doi.org/10.1002/ijc.1440
  23. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  24. Pecorelli S (2009). Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet, 105, 103-4. https://doi.org/10.1016/j.ijgo.2009.02.012
  25. Richter CE, Qian B, Martel M, et al (2009). Ovarian preservation and staging in reproductive-age endometrial cancer patients. Gynecol Oncol, 114, 99-104. https://doi.org/10.1016/j.ygyno.2009.03.032
  26. Shahzad MM, Mangala LS, Han HD, et al (2011). Targeted delivery of small interfering RNA using reconstituted highdensity lipoprotein nanoparticles. Neoplasia, 13, 309-19.
  27. Sivridis E (2001). Angiogenesis and endometrial cancer. Anticancer Res, 21, 4383-8.
  28. Slomovitz BM, Lu KH, Johnston T, et al (2010). A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer, 116, 5415-9. https://doi.org/10.1002/cncr.25515
  29. Thanapprapasr, D (2011). Focal adhesion kinase related gynecologic cancer: a review. Thai J Obstet and Gynecol, 19, 74-80.
  30. Thanapprapasr D, Cheewakriangkrai C, Likittanasombut P, et al (2013). Targeted endometrial cancer therapy as a future prospect. Women's Health, 9, 189-99. https://doi.org/10.2217/whe.13.4
  31. Thanapprapasr D, Hu W, Coleman RL, et al (2012). Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer. Curr Pharm Des, 19, 2713-9.
  32. Thanapprapasr D, Wilailak S (2010). Epidemiology of cancer and cancer control in Thailand. In:Tuncer AM, editor. Cancer report 2010. 1st ed. Ankara; MN Medical and Nobel, 2010:410-3.
  33. Wright JD, Buck AM, Shah M, et al (2009). Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol, 27, 1214-9. https://doi.org/10.1200/JCO.2008.19.8150
  34. Zivanovic O, Carter J, Kauff ND, et al (2009). A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol, 115, 504-9. https://doi.org/10.1016/j.ygyno.2009.08.011

Cited by

  1. Expression and Effects of JMJD2A Histone Demethylase in Endometrial Carcinoma vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3051
  2. Estrogen receptor β: the guardian of the endometrium vol.21, pp.2, 2014, https://doi.org/10.1093/humupd/dmu053
  3. RPRD1B promotes tumor growth by accelerating the cell cycle in endometrial cancer vol.31, pp.3, 2014, https://doi.org/10.3892/or.2014.2990
  4. Methylome Analysis in Chickens Immunized with Infectious Laryngotracheitis Vaccine vol.10, pp.6, 2015, https://doi.org/10.1371/journal.pone.0100476
  5. TESTIN was commonly hypermethylated and involved in the epithelial-mesenchymal transition of endometrial cancer vol.123, pp.5, 2015, https://doi.org/10.1111/apm.12361
  6. The Polymorphism of Hypoxia-inducible Factor-1a Gene in Endometrial Cancer vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10393
  7. Role of exon 7 PTEN Gene in Endometrial Carcinoma vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4521
  8. C-kit Mutations in Endometrial Cancer: Correlation with Tumor Histologic Type vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7449
  9. Regulatory Network of MicroRNAs, Target Genes, Transcription Factors and Host Genes in Endometrial Cancer vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.475
  10. Estrogen related receptor alpha triggers the migration and invasion of endometrial cancer cells via up regulation of TGFB1 pp.1933-6926, 2018, https://doi.org/10.1080/19336918.2018.1477901